A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination with Anti-PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors
Shadia Jalal, MD
Primary Investigator
Brief description of study
Detailed description of study
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: non small cell lung cancer,urothelial carcinoma,solid tumor,squamous cell carcinoma of the head and neck,brain metastasis
-
Age: Between 18 Years - 100 Years
-
Gender: All
Inclusion Criteria
Must have histological or cytological evidence of a diagnosis of cancer that is advanced and/or metastatic
Have adequate organ function
Have a performance status (PS) of less than or equal to on the Eastern Cooperative Oncology Group (ECOG) scale
Have discontinued previous treatments for cancer
Are able to swallow capsules
Exclusion Criteria
Currently enrolled in a clinical study
Have a serious concomitant systemic disorder
Have a symptomatic human immunodeficiency virus infection or symptomatic activated/reactivated hepatitis B or C
Have a significant cardiac condition
Have previously received an indoleamine- 2,3-dioxygenase (IDO) inhibitor
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
